Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + camrelizumab + TACE versus lenvatinib + camrelizumab for advanced liver cancer
ChiCTR2100042270Phase 4Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lenvatinib and camrelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Objective response rate. Started Mar 2021; status: recruiting.
02
Drugs
lenvatinibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100042270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042270.